Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn’s disease patients: the usefulness of rapid testing.

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn’s disease patients: the usefulness of rapid testing. Aliment Pharmacol Ther. 2018 Aug 15;: Authors: Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, Ferrante M Abstract BACKGROUND: Proactive testing of adalimumab serum levels is debated. AIM: To study the association between adalimumab serum levels at week 4 and the development of anti-adalimumab drug antibodies and long-term outcome in anti-TNF naive Crohn’s disease patients. METHODS: Serum samples from 116…

Read More

Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.

Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Aug 10;: Authors: de Francisco R, Castaño-García A, Martínez-González S, Pérez-Martínez I, González-Huerta AJ, Morais LR, Fernández-García MS, Jiménez S, Díaz-Coto S, Flórez-Díez P, Suárez A, Riestra S Abstract BACKGROUND: Little is known about the impact of Epstein-Barr virus (EBV) infection on clinical outcomes in adults with inflammatory bowel disease (IBD). AIM: To evaluate seroprevalence, seroconversion rate and complications associated with EBV infection in an adult IBD cohort attending a…

Read More

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study.

Related Articles Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study. Aliment Pharmacol Ther. 2018 Aug 01;: Authors: Eriksson C, Henriksson I, Brus O, Zhulina Y, Nyhlin N, Tysk C, Montgomery S, Halfvarson J Abstract BACKGROUND: The incidence and short-term outcome of anaemia in inflammatory bowel disease (IBD) are largely unknown. AIM: To determine the incidence, prevalence and clinical outcome of anaemia in terms of resolution of anaemia within 12 months. We also planned to assess risk factors for anaemia in IBD. METHODS: A random…

Read More

Review article: treating-to-target for inflammatory bowel disease-associated anaemia.

Related Articles Review article: treating-to-target for inflammatory bowel disease-associated anaemia. Aliment Pharmacol Ther. 2018 Aug 01;: Authors: Peyrin-Biroulet L, Lopez A, Cummings JRF, Dignass A, Detlie TE, Danese S Abstract BACKGROUND: Iron deficiency has a high prevalence in inflammatory bowel disease (IBD) patients, with negative impact on quality of life and work capacity. AIM: To propose an innovative approach based on early intervention, treating to target and tight monitoring in the management of iron deficiency in IBD patients. METHODS: We conducted a literature review on PubMed and Medline using pre-defined…

Read More

Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the GETAID.

Related Articles Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the GETAID. Aliment Pharmacol Ther. 2018 Aug 02;: Authors: Gagnière C, Bourrier A, Seksik P, Gornet JM, DeWit O, Nancey S, Altwegg R, Abitbol V, Laharie D, Reenaers C, Buisson A, Pariente B, Viennot S, Vuitton L, Stefanescu C, Marteau P, Bouguen G, Cosnes J, Amiot A, GETAID INFOPRO study group Abstract BACKGROUND: Whether healthcare workers with inflammatory bowel disease (IBD) are at increased risk of severe infection due to daily pathogen exposure…

Read More

Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.

Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jul 31;: Authors: Kotze PG, Ma C, Almutairdi A, Al-Darmaki A, Devlin SM, Kaplan GG, Seow CH, Novak KL, Lu C, Ferraz JGP, Stewart MJ, Buresi M, Jijon H, Mathivanan M, Heatherington J, Martin ML, Panaccione R Abstract BACKGROUND: Vedolizumab is an α4β7 integrin antagonist with proven efficacy for inducing and maintaining clinical response and remission in Crohn’s disease (CD) and ulcerative colitis (UC). AIM: To evaluate clinical and objective response…

Read More

Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery? Authors’ reply.

Related Articles Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery? Authors’ reply. Aliment Pharmacol Ther. 2018 Aug;48(3):384-385 Authors: Savoye G, Fumery M, Gower-Rousseau C PMID: 29998504 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29998504?dopt=Abstract

Read More

Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors’ reply.

Related Articles Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors’ reply. Aliment Pharmacol Ther. 2018 Aug;48(3):388-389 Authors: Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M PMID: 29998501 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29998501?dopt=Abstract

Read More
<< Go Back